EL7.AI
StocksMediumUpdated•Originally published 5 October 2026•Updated 5 October 2026•
1 min read

Genmab and AbbVie Announce Positive Phase 3 Results for Epcoritamab

Key Facts

1The Phase 3 EPCORE DLBCL-2 trial demonstrated statistically significant improvement in progression-free survival for DLBCL patients.

Genmab and AbbVie announced positive topline results from a Phase 3 trial evaluating epcoritamab in combination with R-CHOP for newly diagnosed DLBCL patients. GlobeNewswire reported that the EPCORE DLBCL-2 trial demonstrated statistically significant improvement in progression-free survival, with the risk of disease progression or death reduced by 51%.

The trial is the first Phase 3 study of a bispecific antibody combination to show clinical improvement in frontline DLBCL treatment. Regarding market performance, ABBV closed at $262.82 and GMAB closed at $34.75 on October 2, 2026.

Latest Updates · 1

  1. Notable·

    Update: Genmab's Rina-S demonstrated a 45.9% confirmed response rate in Phase 1/2 trials for platinum-resistant ovarian cancer on October 5, 2026. Following these results, analysts set a new price target for GMAB at $54.00.